MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Imidacloprid

CAS No. : 138261-41-3

MCE 站：Imidacloprid

产品活性：Imidacloprid 是一种有效且广泛使用的新烟碱类农药，用于控制谷物，蔬菜，茶叶和棉花的害虫。

研究领域：Others

作用靶点：Others

In Vitro: Insulin stimulated glucose uptake is reduced by imidacloprid in adipocytes (3T3-L1), hepatocytes (HepG2), and myotubes (C2C12) cell culture models. Treatment with imidacloprid reduced phosphorylation of protein kinase B (AKT), one of the major regulators of insulin signaling, without changing overall AKT expression. imidacloprid reduced phosphorylation of ribosomal S6 kinase (S6K), which is a downstream target of AKT and also a feed-back inhibitor of insulin signaling.

In Vivo: Imidacloprid in high doses causes deterioration in cognitive functions particularly in infant rats, and this deterioration may be associated with changes in the expressions of related genes. Learning activities are diminished significantly at 2 and 8 mg/kg doses in the infant model groups and at 8 mg/kg dose in adult rats. Also, expression levels of GRIN1, SYP and GAP-43 are found to be insignificantly altered. Early developmental exposure to imidacloprid has both early-life and persisting effects on neurobehavioral function in zebrafish. In larvae, developmental imidacloprid exposure at both doses significantly decreased swimming activity. In adolescent and adult fish, developmental exposure to imidacloprid significantly decreased novel tank exploration and increased sensorimotor response to startle stimuli. Decrease in the body weight gain is observed at 20 mg/kg/day and at necropsy the relative body weights of liver, kidney and adrenal is also significantly increased at this dose level. The spontaneous locomotor activity is also decreased at highest dose exposure where as there are no significant changes in hematological and urine parameters. The brain, liver and kidney of rats exposed with high dose of imidacloprid has showed mild pathological changes. Imidacloprid at 20 mg/kg has produced significant changes in SOD, CAT, GPx, GSH, LPO in liver; SOD, CAT, and GPx in brain and LPO in kidney. Imidacloprid at high dose, specifically suppresses cell-mediated immune response as is evident from decreased DTH response and decreased stimulation index of T-lymphocytes to PHA. Prominent histopathological alterations are also observed in spleen and liver. Histopathological analysis of footpad sections of mice reveal dose-related suppression of DTH response.

相关产品：Covalent Screening Library Plus  |  Bioactive Compound Library Plus  |  Covalent Screening Library  |  PEG300  |  SBE-β-CD  |  Corn oil  |  Tween 80  |  Polyethylene glycol 12-hydroxystearate  |  JC-1  |  Lipopolysaccharides  |  DTT  |  (2-Hydroxypropyl)-β-cyclodextrin  |  Methyl-β-cyclodextrin  |  CFSE  |  Digitonin  |  D-Luciferin potassium salt  |  Thiazolyl Blue  |  Biotin  |  3X FLAG peptide TFA  |  Monocrotaline  |  Nile Red  |  Auxinole  |  Tocofersolan  |  FLAG peptide  |  IPTG  |  Yoda 1  |  Cremophor EL  |  GsMTx4 TFA  |  Propidium Iodide  |  DAPI dihydrochloride  |  Calcein-AM  |  Sodium carboxymethyl cellulose (Viscosity:800-1200 mPa.s)

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。